The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical series, TMPRSS2:ERG fusion was identified in 50% of the tumors. Here, we report on a population-based cohort of men with localized prostate cancers followed by expectant (watchful waiting) therapy with 15% (17/111) TMPRSS2:ERG fusion. We identified a statistically significant association between TMPRSS2:ERG fusion and prostate cancer specific death (cumulative incidence ratio ¼ 2.7, Po0.01, 95% confidence interval ¼ 1.3-5.8).
At initial diagnosis, 91% of the 234 460 men with prostate cancer identified in the United States in 2006 will have clinically localized disease with a 100% 5-year survival rate (Jemal et al., 2006) . Current treatment options for localized prostate cancer include: radical prostatectomy, radiotherapy or expectant (watchful waiting) therapy. Given the excellent short-term outcome regardless of treatment, the risks of therapy must be balanced with the risk of disease progression. One randomized trial evaluated the benefit of radical prostatectomy over expectant therapy. The Scandinavian Prostate Cancer Group Study No. 4 demonstrated that surgery significantly decreased the risk of death from prostate cancer (Holmberg et al., 2002; Bill-Axelson et al., 2005) . However, to prevent one prostate cancer-specific death, 19 men are subjected to treatment and some men died notwithstanding radical surgery. Warlick et al. (2006) reported that after defining a minimal risk group using pathological and clinical parameters, expectant therapy was not associated with an increase in disease progression when definitive treatment was eventually administered. Thus, the acceptance of expectant therapy hinges on accurate risk assessment for prostate cancer disease progression. The identification of the TMPRSS2:ETS fusion in prostate cancer suggests that distinct molecular subtypes may further define risk for disease progression (Tomlins et al., 2005; Soller et al., 2006) . The most common gene fusion is TMPRSS2:ERG found in approximately 50% of the surgical-based cohorts studied to date.
In early studies, the gene fusions of the 5 0 -untranslated region of TMPRSS2 (21q22.3) with the ETS transcription factor family members, estrogen-regulated gene (ERG) (21q22.2), ETV1 (7p21.2) (Tomlins et al., 2005) , or ETV4 (Tomlins et al., 2006) provide a mechanism for the overexpression of the ETS genes in prostate cancers. Furthermore, the fusion of an androgen-regulated gene, TMPRSS2, and an oncogene suggests that disease progression may vary based on these molecular subtypes. A common mechanism for gene fusion is loss of 2.8 Mb of genomic DNA between TMPRSS2 and ERG (Perner et al., 2006) (Figure 1a and b). In the current study, we characterize a population-based cohort with respect to TMPRSS2:ERG fusion and explore the risk of metastases or prostate cancer-specific death based on the presence of the common TMPRSS2:ERG fusion.
The Watchful Waiting cohort has been previously described and details can be found in the Supplementary material (Johansson et al., 1989 (Johansson et al., , 1992 (Johansson et al., , 1997 (Johansson et al., , 2004 Andren et al., 2006) . In brief, the cohort comprises 252 men with early prostate cancer (T1a-b, Nx, M0) diagnosed by transurethral resection of the prostate or transvesical adenoma enucleation for symptomatic benign prostatic hyperplasia at the Ö rebro University Hospital, Sweden between 1977 and 1991. Baseline evaluation at diagnosis included physical examination, chest radiography, bone scan and skeletal radiography (if needed). Patients were followed expectantly (without curative treatment) and received clinical exams, laboratory tests and bone scans every 6 months during the first 2 years after diagnosis and subsequently at 12-month intervals. Symptomatic disease progression was treated with androgen deprivation therapy or palliative radiotherapy.
The patients were followed until death from prostate cancer, or censored at time of other death or until end of observation period in October 2005. No patients were lost to follow up. The end point of the present study was lethal prostate cancer, defined as development of distant metastases or prostate cancer as the underlying cause of death (median follow-up time 9.1 years, maximum 28 years).
All transurethral resection of the prostate (TURP) samples were reviewed by one pathologist to confirm a diagnosis of prostate cancer, determine the Gleason score and nuclear grade, and estimate the tumor burden as described previously (Andren et al., 2006) . This work was performed before the evaluation of the molecular data. A tissue microarray was assembled using a manual arrayer (Rubin et al., 2005) . The frequency of the TMPRSS2:ERG rearrangement in prostate cancer was assessed using a fluorescence in situ hybridization (FISH) assay (Perner et al., 2006) . This FISH assay is an indirect test and therefore cannot directly confirm fusion of TMPRSS2:ERG (see Supplementary materials for details). However, as we previously reported (Tomlins et al., 2005) , 5 0 RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) analysis and sequencing of the reverse-transcription-polymerase chain reaction (RT-PCR) product from prostate cancer cases with ERG over expression revealed a fusion of TMPRSS2 with ERG by quantitative PCR (QPCR) and/or RACE. This demonstrates that almost all prostate cancer samples with marked overexpression of ERG have a rearrangement, and the overexpression occurs in about the same number of cases as the rearrangement.
We characterized 111 cases for TMPRSS2:ERG fusion. Ninety-two of the cases were characterized by FISH (Figure 1a and b) , where 19, for which FISH failed, were characterized by QPCR. The technical difficulties with the FISH assay included the absence of diagnostic material to evaluate and weak probe signals. The samples, which were not evaluable, had lower stage and lower Gleason Score.
In this population-based cohort of men diagnosed with localized cancer, the frequency of TMPRSS2:ERG . This hybridization pattern is consistent with a deletion of B2.8 Mb of genomic DNA encompassing the telomeric portion of the ERG probe. (c) In a cumulative incidence regression model, we evaluated TMPRSS2:ERG as a determinant for the cumulative incidence or metastases or prostate cancer-specific death. We observed a significant difference in survival in favor of TMPRSS2:ERG gene fusion negative cases. CIR (CIR ¼ 2.7, Po0.01, 95%CI ¼ 1.3-5.8) was performed using the weighted estimating equation as implemented in cmprsk R library (R Development Core Team, 2006) . Other statistical analysis was performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA).
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fusion was 15% (17/111). TMPRSS2:ERG fusionpositive tumors were more likely to have a higher Gleason score (two-sided P ¼ 0.01) ( Table 1) . To assess the relation of fusion status and lethal prostate cancer, we employed cumulative incidence regression (Kalbfleisch and Prentice, 2002) to account for competing causes of death over time. We observed a statistically significant association between the presence of the TMPRSS2:ERG fusion and metastases or diseasespecific death (Figure 1c ) with a cumulative incidence ratio (CIR) of 2.7 (Po0.01, 95% confidence interval (CI) ¼ 1.3-5.8). When adjusting for Gleason score, the CIR was 1.8 (P ¼ 0.2 and 95% CI ¼ 0.6-5.3). Based on the homogeneity of the TMPRSS2:ERG fusion in cells in a given tumor (Perner et al., 2006) and its presence in invasive prostate cancer and approximately 20% of high-grade prostate cancer with associated gene fusion (Perner et al., in press), we believe this to be an early event. To assess the association of ERG overexpression with gene fusion in this population-based cohort, we performed QPCR for the ERG gene (ERG f: exon 5-6, CGCAGAGTTATCGTGCCAGCAGAT and ERG r: exon 5-6, CCATATTCTTTCACCGCCCACTCC) as described recently (Tomlins et al., 2005) , in a subset of 28 cases. High ERG expression was seen in 12/12 TMPRSS2:ERG fusion prostate cancers in contrast to 2/ 16 prostate cancers without TMPRSS2:ERG fusion (Po0.0005) (Figure 2) . Thus, 86% of prostate cancer cases with high ERG expression in this subset had the TMPRSS2:ERG fusion. This result confirms our previous finding where 19 of 20 prostate cancer cases with ERG overexpression were shown to have TMPRSS2:ERG rearrangement by sequencing (Tomlins et al., 2005) .
Interestingly, high ERG expression was seen as protective in the only other prostate cancer study (Petrovics et al., 2005) examining ERG, where high levels of ERG transcription were associated with a lower incidence of prostate-specific antigen (PSA) biochemical failure. The findings by Petrovics need to be viewed with caution, as biochemical failure is a poor surrogate end point for clinically meaningful end points, including clinical relapse and death as demonstrated by three recent studies. Porter et al. (2006) observed 45.5% PSA biochemical failure in a radical prostatectomy series but prostate cancer-specific death occurred in only 18.5% of the population with a follow-up time of up to 25 years. Carver et al., 2006 reported on a population of men with T3 prostate cancer who underwent radical prostatectomy, only 36% with PSA biochemical failure had disease progression. Ward et al., 2003 found that in a population of 3897 radical prostatectomy patients, only 8.3% of the men with PSA biochemical failure died of prostate cancer. Thus PSA failure is associated with prostate cancer-specific death but the majority of men with PSA biochemical failure will die of other causes. Therefore, the association between TMPRSS2:ERG fusion status and prostate cancer death is much more reliable relationship. 
The Ö rebro Watchful Waiting cohort represents a treatment naı¨ve population drawn from a strictly defined catchment area for 190 000 inhabitants living in Ö rebro. The frequency of TMPRSS2:ERG fusion in this watchful waiting population is lower than the 55% (16/29) reported by Tomlins et al. (2005) and 78% (14/ 18) reported by Soller et al. (2006) and 49.2% (58/118) reported by Perner et al. (2006) . These differences might be explained by the lower percentage of high-grade cases in this watchful waiting cohort as compared to the other non-population-based studies.
In summary, these data suggest that the TMPRSS2:ERG fusion may contribute to a more aggressive prostate cancer phenotype and perhaps account in part to higher grade prostate cancer. In addition, this study supports the critical role of ERG as an oncogene in prostate cancer.
